Cancer News
Cancer Education and Research Institute® (CERI)'s Cancer Education Programs
Our Team of cancer experts at Cancer Education and Research Institute® (CERI)'s, formerly Cancer Research Simplified, provides you with the most reliable, most up-to-date, and simplified cancer information available. Our educational programs quickly became trusted and highly sought after worldwide.
CERI strongly stands behind the importance of cancer patient empowerment and is a worldwide leading source for simplified, multi-language cancer education. Knowledge is power and empowerment is the key for greater treatment success, early diagnosis, as well as cancer prevention.
For any questions or requests, please submit your inquiry at our CERI Personalized Patient Program™ page.
CERI strongly stands behind the importance of cancer patient empowerment and is a worldwide leading source for simplified, multi-language cancer education. Knowledge is power and empowerment is the key for greater treatment success, early diagnosis, as well as cancer prevention.
For any questions or requests, please submit your inquiry at our CERI Personalized Patient Program™ page.
Immunotherapy - Personalized Medicine
Terminal Bile Duct Cancer completely eradicated in an UK immunotherapy + chemotherapy combo trial - Importance of PERSONALIZED MEDICINE
Aygün Sahin, MSc, PhD | CEO, President, and Cancer Lead, Cancer Education and Research Institute (CERI)
Robert Glynn, 51 from Worsley, Greater Manchester, UK had 12 months to live.
His cancer was only picked up by chance after series of scans and blood tests when he got an infection in his gall bladder.
In August 2020, at age of 49, he was diagnosed with intrahepatic bile duct cancer (intrahepatic cholangiocarcinoma - a subgroup of biliary tract cancer)
His cancer was at an advanced stage and had spread to his adrenal gland.
He was offered the opportunity to participate in a immunotherapy + chemotherapy combo clinical trial.
Before the trial, his tumor was analyzed to check for any genetic alterations (genetic mutations).
The tumor had a high mutation burden (large numbers of genetic mutations in the tumor cells).
This suggested that he may potentially have a good response to experimental treatment.
The tumor in his liver shrank from 12cm to 2.6cm, and the tumor in his adrenal gland shrank from 7cm to 4.1cm.
This meant that he was able to undergo surgery to remove his tumors.
Surgeons found only dead tissue in the tumors, which meant the treatment had killed off all the cancer cells.
The clinical trial was led by Professor Juan Valle, at the Christie and a world-leading expert in biliary tract cancer.
“Robert has done very well on this combination due to his tumor having a high mutation burden, or a high number of genetic mutations. Most patients with this diagnosis do not have as many mutations in their cancer cells so the treatment won’t be as effective, but it does highlight the importance of personalized medicine."
His cancer was only picked up by chance after series of scans and blood tests when he got an infection in his gall bladder.
In August 2020, at age of 49, he was diagnosed with intrahepatic bile duct cancer (intrahepatic cholangiocarcinoma - a subgroup of biliary tract cancer)
His cancer was at an advanced stage and had spread to his adrenal gland.
He was offered the opportunity to participate in a immunotherapy + chemotherapy combo clinical trial.
Before the trial, his tumor was analyzed to check for any genetic alterations (genetic mutations).
The tumor had a high mutation burden (large numbers of genetic mutations in the tumor cells).
This suggested that he may potentially have a good response to experimental treatment.
The tumor in his liver shrank from 12cm to 2.6cm, and the tumor in his adrenal gland shrank from 7cm to 4.1cm.
This meant that he was able to undergo surgery to remove his tumors.
Surgeons found only dead tissue in the tumors, which meant the treatment had killed off all the cancer cells.
The clinical trial was led by Professor Juan Valle, at the Christie and a world-leading expert in biliary tract cancer.
“Robert has done very well on this combination due to his tumor having a high mutation burden, or a high number of genetic mutations. Most patients with this diagnosis do not have as many mutations in their cancer cells so the treatment won’t be as effective, but it does highlight the importance of personalized medicine."
You may like to watch these videos:
|
|
|
References:
- Man with terminal cancer cleared of disease thanks to UK drug trial https://www.independent.co.uk/news/uk/greater-manchester-covid-surgeons-manchester-united-b2253314.html (accessed 12/30/2022)
- Man given a year to live now cancer-free after immunotherapy tiral https://www.theguardian.com/science/2022/dec/30/man-year-to-live-now-cancer-free-after-immunotherapy-trial (accessed 1/3/2023)
- Daniel H Ahn and Tanios Bekaii-Saab. Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications https://pubmed.ncbi.nlm.nih.gov/28480068/ (accessed 1/3/2023)
Do you need help with cancer diagnosis?
Please fill the application form on our CERI Personalized Patient Program page - we CAN help you!
#Empowermentagainstcancer™ #CERICancerEducation #CERICares
#cancer #glioblastoma #gbm #bileductcancer #cholangiocarcinoma #biliarytractcancer #clinicaltrial #immunotherapy #chemotherapy #cancerfree #eradicatingcancer #metastaticcancer #cancereducation #cancerresearch #cancertreatment #canceredinstitute
GET YOUR FREE ARTICLE: Make sure to get your free article as our gift to you! Go to: canceredinstitute.org/ceri-simplified-cancer-research-articles
CORONAVIRUS PAGE: For our educational and up-to-date informational page on Coronavirus, go to: canceredinstitute.org/coronavirus
FOLLOW US for DAILY information and updates:
CORONAVIRUS PAGE: For our educational and up-to-date informational page on Coronavirus, go to: canceredinstitute.org/coronavirus
FOLLOW US for DAILY information and updates:
- INSTAGRAM: instagram.com/canceredinstitute
- FACEBOOK: facebook.com/canceredinstitute
- Twitter: twitter.com/canceredinst
- LinkedIn: linkedin.com/company/canceredinstitute
You might also like:
|
|
|
Disclaimer: We can not assume responsibility of misinterpretation of content.
Please donate to support our program - help us save MORE lives!
